JPWO2021089588A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021089588A5 JPWO2021089588A5 JP2022525630A JP2022525630A JPWO2021089588A5 JP WO2021089588 A5 JPWO2021089588 A5 JP WO2021089588A5 JP 2022525630 A JP2022525630 A JP 2022525630A JP 2022525630 A JP2022525630 A JP 2022525630A JP WO2021089588 A5 JPWO2021089588 A5 JP WO2021089588A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- cancer
- seq
- inventions
- once
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962930512P | 2019-11-04 | 2019-11-04 | |
| US62/930,512 | 2019-11-04 | ||
| US202063080361P | 2020-09-18 | 2020-09-18 | |
| US63/080,361 | 2020-09-18 | ||
| PCT/EP2020/080892 WO2021089588A1 (en) | 2019-11-04 | 2020-11-04 | Her2/4-1bb bispecific fusion proteins for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023502876A JP2023502876A (ja) | 2023-01-26 |
| JPWO2021089588A5 true JPWO2021089588A5 (enExample) | 2023-11-13 |
Family
ID=73598820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022525630A Pending JP2023502876A (ja) | 2019-11-04 | 2020-11-04 | がんの治療のためのｈｅｒ２／４－１ｂｂ二重特異性融合タンパク質 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240166763A1 (enExample) |
| EP (1) | EP4054718A1 (enExample) |
| JP (1) | JP2023502876A (enExample) |
| KR (1) | KR20220097952A (enExample) |
| CN (1) | CN116348478A (enExample) |
| AU (1) | AU2020379176A1 (enExample) |
| CA (1) | CA3154881A1 (enExample) |
| WO (1) | WO2021089588A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230366884A1 (en) | 2020-09-18 | 2023-11-16 | Pieris Pharmaceuticals Gmbh | Biomarker methods and uses |
| EP4644417A4 (en) * | 2022-12-30 | 2026-02-11 | Abclon Inc | AFFICORPS SPECIFICALLY BINDING TO CD137 AND ITS USE |
| CN116103244A (zh) * | 2023-04-12 | 2023-05-12 | 河北科技大学 | 一种单信号激活型til细胞的制备方法及应用 |
| WO2025211753A1 (en) * | 2024-04-03 | 2025-10-09 | Yuhan Corporation | Anti-her2/anti-4-1bb bispecific antibody for treatment of biliary tract cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| JPH07501451A (ja) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | 多価抗原結合タンパク質 |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| EP1430136A1 (en) | 2001-09-27 | 2004-06-23 | Pieris ProteoLab AG | Muteins of apolipoprotein d |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| AU2003275958A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| WO2015104406A2 (en) * | 2014-01-13 | 2015-07-16 | Pieris Ag | Multi-specific polypeptide useful for localized tumor immunomodulation |
| RU2736312C2 (ru) | 2015-05-04 | 2020-11-13 | ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ | Белки, специфичные в отношении cd137 |
| AU2016258977C1 (en) * | 2015-05-04 | 2022-07-14 | Pieris Pharmaceuticals Gmbh | Anti-cancer fusion polypeptide |
-
2020
- 2020-11-04 EP EP20815720.6A patent/EP4054718A1/en not_active Withdrawn
- 2020-11-04 KR KR1020227018948A patent/KR20220097952A/ko active Pending
- 2020-11-04 WO PCT/EP2020/080892 patent/WO2021089588A1/en not_active Ceased
- 2020-11-04 CA CA3154881A patent/CA3154881A1/en active Pending
- 2020-11-04 AU AU2020379176A patent/AU2020379176A1/en not_active Abandoned
- 2020-11-04 JP JP2022525630A patent/JP2023502876A/ja active Pending
- 2020-11-04 US US17/755,482 patent/US20240166763A1/en not_active Abandoned
- 2020-11-04 CN CN202080091568.2A patent/CN116348478A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11168144B2 (en) | Activatable anti-PDL1 antibodies, and methods of use thereof | |
| JP2020147572A (ja) | リンパ球における阻害経路の中和 | |
| CN117222663A (zh) | 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法 | |
| CN107614530A (zh) | 用于多发性骨髓瘤（mm）的治疗 | |
| JP2019505785A5 (enExample) | ||
| WO2023061472A1 (zh) | 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| CN109663130B (zh) | Pd-1抗体和mek抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| US20230398229A1 (en) | Antibody drug conjugates comprising sting agonists, combinations and methods of use | |
| WO2020119758A1 (zh) | Il-15蛋白复合物联合pd-l1抗体用于治疗肿瘤疾病的用途 | |
| JP7495489B2 (ja) | ＰＤ－１およびＴＧＦβを標的化する組換えタンパク質 | |
| JP2019505784A5 (enExample) | ||
| KR102239752B1 (ko) | 종양 특이적 약물복합체와 항pd-l1 항체를 유효성분으로 하는 암 예방 또는 치료를 위한 병용 투여용 약학 조성물 | |
| CN120437288A (zh) | 治疗卵巢癌的药物组合 | |
| JPWO2021089588A5 (enExample) | ||
| KR20230069957A (ko) | 암을 갖는 환자의 치료를 위한 pd-1 길항제 및 lag3 길항제 및 렌바티닙 또는 이의 약학적으로 허용가능한 염의 병용 요법 | |
| TW201809013A (zh) | 用於藥物遞送之抗體融合蛋白 | |
| CN106963950B (zh) | 用于治疗肿瘤的联合用药物 | |
| EP4501959A1 (en) | Antibodies that specifically bind to api5 protein | |
| KR102940576B1 (ko) | Api5 단백질에 특이적으로 결합하는 항체 | |
| US20250019462A1 (en) | Antibodies that specifically bind to api5 protein | |
| JP2019505516A (ja) | インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法 | |
| CN121622859A (zh) | TGF-β受体融合蛋白在制备治疗胃及胃食管结合部腺癌的药物中的用途 | |
| CN113993544A (zh) | 用于治疗egfr高表达的癌症的多变剂量方法 | |
| EA050171B1 (ru) | Способы и комбинации для лечения рака с применением антител, являющихся ингибиторами иммунных контрольных точек | |
| EA046745B1 (ru) | Способ лечения рака активируемым антителом против pdl1 |